Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.54 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Citrulline SCHEMBL20588 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL215403 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL288641 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20587 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL9070200 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL15909605 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL4542892 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL15909604 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL22426116 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20742804 | 0.98 | OTC (0.57) | OTCDDAH1GSRNOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026098644-A1 | TARGETED PROTEIN DEGRADATION AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京森妙生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260131015-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2026-05-14 | — | — | US | claimed |
| US-20260097117-A1 | CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2026-04-09 | — | — | US | claimed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| EP-4720086-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | claimed |
| EP-4598587-A1 | NEODEGRADER CONJUGATES | Orum Therapeutics Inc. (KR) | 2025-08-13 | — | — | EP | claimed |
| EP-4126068-A1 | CONJUGATES | Orum Therapeutics Inc. (KR) | 2023-02-08 | — | — | EP | claimed |
| CN-115505171-A | Novel organic zinc salt PVC compound heat stabilizer and preparation method and application thereof | 浙江工业大学 | 2022-12-23 | — | — | CN | claimed |
| WO-2022254377-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2022-12-08 | — | — | WO | claimed |
| CN-115184478-A | Quantitative analysis method of 70 amino substances in blood plasma based on 'derivatization in fiber' strategy and application thereof | 沈阳药科大学 | 2022-10-14 | — | — | CN | claimed |
| WO-2022096387-A1 | APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND PROCESS OF CALCULATING SET FLOW RATES IN A MEDICAL APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD | GAMBRO LUNDIA AB (SE) | 2022-05-12 | — | — | WO | claimed |
| CN-109196004-B | Engineered scaffold for vascularized tissue repair | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | claimed |
| US-20140057850-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | ORGANOBALANCE GMBH (DE) | 2014-02-27 | — | — | US | claimed |
| EP-2673288-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | Organo Balance GmbH (DE) | 2013-12-18 | — | — | EP | claimed |
| CN-103415531-A | Peptide for use in the treatment of skin conditions | ORGANO BALANCE GMBH | 2013-11-27 | — | — | CN | claimed |
| WO-2012107244-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | ORGANOBALANCE GMBH (DE) | 2012-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057850-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | NGLY1, FPR3, CUTA | OTC 2152/4885DDAH1 2635/4885GSR 4004/4885 |
| US-20260097117-A1 | CONJUGATES | CRBN, CUL4B, CUL4A | OTC 4457/4885DDAH1 2992/4885GSR 4768/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | OTC 1979/4885DDAH1 567/4885GSR 2148/4885 |
| US-20260131015-A1 | NEODEGRADER CONJUGATES | FCGR2A, FCGR3B, CD47 | OTC 3190/4885DDAH1 1846/4885GSR 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.